Wireless Intracranial Pressure Monitoring Implants 2026
Wireless ICP Monitoring Implant Technology Landscape
Wireless intracranial pressure monitoring implants converge MEMS sensing, RF telemetry, and biocompatible materials to replace wired neurosurgical systems. This dataset spans 40+ patent documents across CN, US, GB, EP, IN, WO, and AU jurisdictions from 2009 to 2025.
Five Technical Sub-Domains Shaping Wireless ICP Implants
Wireless implantable ICP monitoring systems seek to replace traditional wired, transcranial catheter systems with fully or partially implanted assemblies that transmit pressure data through the skull to an external reader or wearable hub. The field spans five principal technical sub-domains: active RF-powered implants, passive LC-resonant MEMS sensors, gas-reference pressure transduction, multi-parameter integrated implants, and non-invasive proxy modalities.
The foundational phase (2009–2012) saw early Chinese filings from Beijing Ruizhicong Technology establish the RF-command, load-modulation architecture, where an external unit energizes and commands the implant, harvesting RF power and returning encoded pressure data. UT-Battelle’s 2009 US patent traces its lineage to a 1999 filing, underscoring that basic telemetric ICP concepts predate the modern wireless era.
The development phase (2015–2019) saw substantial acceleration. The University of Chinese Academy of Sciences introduced passive, battery-free LC-resonant MEMS systems. Branchpoint Technologies filed its foundational PCT for a gas-reference hermetically sealed catheter system in 2017. Clinical use of telemetric ICP devices (NEUROVENT-P-tel) for idiopathic intracranial hypertension home monitoring was confirmed as early as 2014–2020, validating 18 of 20 patient diagnoses.
The maturation phase (2020–2025) brought diversification in retrieved records: Branchpoint & Aura expanded with multiple active US and EP grants through November 2025, Johns Hopkins filed multimodal cranial implants, Southeast University introduced graphene-PDMS passive sensors, and a cluster of Indian filings from NIMS University Rajasthan emerged covering non-invasive wearable ICP estimation. In this dataset, China accounts for approximately 20 of 40 CN-jurisdiction patents across 12 distinct Chinese assignees.
Filing Trends and Technology Cluster Distribution
Analysis of retrieved patent records reveals a bipolar geographic concentration — China dominates by filing volume across fragmented assignees, while the US and EU host fewer but more commercially advanced and clinically validated portfolios. The dataset spans five technology clusters with distinct innovation timelines.
Patent Filing Count by Technology Cluster (Dataset Snapshot)
Active RF-powered implants represent the most populated technology cluster in this dataset, followed by passive LC-MEMS systems and gas-reference catheter architectures; multimodal and non-invasive clusters are emerging but smaller in retrieved records.
↗ Click bars to exploreFiling Activity by Phase (Dataset Snapshot)
In this dataset, filing activity accelerated markedly in the 2015–2019 development phase and continued into 2020–2025 maturation, with the earliest foundational filings concentrated in 2009–2012 from Chinese and US assignees.
↗ Click bars to exploreKey Clinical and Research Domains for Wireless ICP Monitoring
Retrieved records confirm wireless ICP monitoring implants address four principal application areas: neurocritical TBI care, long-term CSF disorder management, post-surgical ward monitoring, and BCI-integrated neuromodulation research — with a parallel track of non-invasive proxy modalities for resource-limited settings.
Traumatic Brain Injury Neurocritical Care
TBI is the dominant driver in this dataset, with the wireless LCP-based ICP sensor literature confirming a 0–60.12 mmHg operating range and sensitivity of 25.62 µV/mmHg. The first-in-human integration of an FDA-cleared wireless ICP sensor within a customized cranial implant was performed following decompressive hemicraniectomy for a gunshot wound. Branchpoint & Aura’s US patent (2018) explicitly targets acute TBI ICP thresholds, and Johns Hopkins’ WO 2021 filing lists TBI as the primary use case.
Neurocritical MonitoringHydrocephalus and CSF Disorders
Two clinical literature records in this dataset validate long-term ambulatory telemetric ICP monitoring for idiopathic intracranial hypertension and normal pressure hydrocephalus. The NEUROVENT-P-tel telemetric system enabled home ICP telemonitoring in 20 IIH patients (2014–2020), confirming 18 of 20 diagnoses. An observational study of implantable telesensors in hydrocephalus patients showed significant reductions in neurosurgical service demand and costs.
Ambulatory ICP MonitoringPost-Surgical Hospital Ward Monitoring
Guangzhou Fengding Medical Technology’s wireless network-based multi-user ICP system (CN 2022) integrates IBP, MAP, ICP, intracranial temperature, and CPP for multiple patients simultaneously. Shenzhen Second People’s Hospital filed a post-operative intelligent wireless ICP monitoring device (CN 2021) incorporating automated alert and treatment initiation logic. These filings address the clinical need for centralized, continuous neurosurgical ward monitoring without wired tethering.
Multi-Patient MonitoringNon-Invasive ICP Proxy Wearables
A 2025 cluster of five Indian filings from NIMS University Rajasthan covers wearable devices estimating ICP non-invasively using ONSD ultrasound spectacles, combined ONSD and pupillometry spectacles, tympanic membrane displacement ear probes, and a multi-sensor helmet integrating EEG, NIRS, TCD, and TMD with AI/ML processing and HIPAA/GDPR-compliant wireless transmission. These devices target emergency and resource-limited settings where neurosurgical implant procedures are unavailable.
Non-Invasive EstimationLeading Assignees in Wireless ICP Implants — Dataset Snapshot
In retrieved records, Branchpoint & Aura Development LLC holds the most active implantable ICP patent position in Western jurisdictions, with at least 8 patent documents across US and EP filings (2017–2025) in this dataset. Beijing Ruizhicong Technology and NeuCen Biomedical each contributed 4 filings in retrieved records, representing early foundational and active catheter-based architectures respectively.
Top Assignees by Filing Count in Retrieved Records (Dataset Snapshot)
↗ Click bars to exploreBranchpoint & Aura Development LLC
Branchpoint & Aura Development LLC holds 8 patent documents in retrieved records, spanning US and EP jurisdictions from 2017 (foundational PCT as Branchpoint Technologies) through a November 2025 US grant. Their core technology is a hermetically sealed gas-reference chamber connected to a pressure-conduction catheter with ports, enabling ICP, temperature, and head-position monitoring without direct fluid-to-electronics contact. At least 4 US grants (2018–2025) and 2 active EP grants are confirmed in this dataset, and the platform has achieved FDA clearance and first-in-human publication.
United StatesNeuCen Biomedical Co., Ltd.
NeuCen Biomedical Co., Ltd. holds 4 patent documents in retrieved records across US and GB jurisdictions, filed between 2017 and 2020. Their technology features a catheter-based strain gauge detecting radial, circumferential deformation or diaphragm distortion within a titanium alloy catheter of 2 mm outer diameter, coupled to an RF coil transceiver. The GB portfolio (2 active grants, 2017 and 2020) and US portfolio (1 active grant, 2020) demonstrate a deliberate multi-jurisdiction IP strategy for their wireless ICP catheter design.
Taiwan — Multi-JurisdictionFour Converging Technology Frontiers in Wireless ICP (2024–2025)
The most recent filings in this dataset (2024–2025) reveal convergence around multimodal intracranial probes, BCI-ICP integration, advanced passive sensor materials, and universal cranial implant power platforms — alongside a parallel non-invasive AI-assisted estimation track.
Graphene-PDMS Passive Sensors for Battery-Free Chronic Implants
Southeast University’s 2024 CN filing incorporates graphene-doped PDMS (Gr-PDMS) as the pressure-sensitive medium within an inductive LC resonator, demonstrating that nanomaterial engineering is entering the implant sensor space. The Gr-PDMS composite shifts the LC resonant frequency proportionally to ICP, enabling inductive readout without any implanted battery. This approach is claimed to offer improved sensitivity, biocompatibility, and long-term stability over conventional MEMS capacitive designs.
BCI-ICP Convergence via Flexible Minimally Invasive Probes
Tianjin University’s 2025 CN filing couples EEG microarray electrodes with ICP sensors on a flexible probe delivered intrathecally via lumbar puncture, minimizing cranial opening and infection risk. This positions ICP monitoring within the broader brain-computer interface infrastructure investment wave, integrating neural signal acquisition and intracranial pressure into a single minimally invasive device. The Regents of the University of California (US 2020) filed a distributed microscale wireless sensor network for intracranial implants with an epidermal wearable RF hub, representing an earlier convergence signal.
Active RF-Powered Implants vs. Passive LC-MEMS Systems
Click any row to explore further.
| Dimension | Active RF-Powered Implants | Passive LC-MEMS Systems |
|---|---|---|
| Power Source | On-board battery (primary or rechargeable) or inductive energy harvesting from external unit | No implanted battery; fully powered by external inductive field |
| Example Assignees (dataset) | Branchpoint & Aura Development LLC, NeuCen Biomedical, Chuanghui Medical, Beijing Ruizhicong | University of Chinese Academy of Sciences, Southeast University (Gr-PDMS) |
| Sensing Principle | Piezoelectric, piezoresistive, strain-gauge, or capacitive sensor with on-board signal processing | MEMS capacitive pressure sensor shifts LC resonant frequency; detected inductively by external coil |
| Battery Replacement Surgery | Required for primary-battery variants; rechargeable variants mitigated by wireless charging | Not required; no implanted battery |
| Interrogation Range | Longer range achievable via WiFi, Bluetooth, or proprietary RF transceivers | Limited by inductive coupling distance; external patch coil must be proximate to skull |
| Multimodal Capability | Readily integrates ICP with temperature, rSO2, EEG, hemorrhage detection (multiple 2021–2025 filings) | Currently single-parameter (ICP only) in retrieved records |
| Patent Status (Dataset) | Mix of active (Branchpoint US/EP, NeuCen US/GB) and inactive (Beijing Ruizhicong all inactive) filings | Active CN filings (Univ. Chinese Academy of Sciences 2016, 2019); Southeast University pending (2024) |
| FDA / Clinical Validation | Branchpoint system FDA-cleared; first-in-human published; NEUROVENT-P-tel validated in 20 IIH patients | No FDA clearance documented in retrieved records; clinical translation stage unclear |
Frequently Asked Questions: Wireless ICP Monitoring Implants
Based on retrieved records, the five sub-domains are: (1) active RF-powered implants with on-board microcontrollers and wireless transceivers; (2) passive LC-resonant MEMS sensors powered and read out inductively without any implanted battery; (3) gas-reference pressure transduction systems using hermetically sealed chambers; (4) multi-parameter integrated implants combining ICP with temperature, cerebral oxygenation, and electrophysiology; and (5) non-invasive and wearable proxy modalities leveraging ONSD, TMD, TCD, and photoplethysmography.
In retrieved records, Branchpoint & Aura Development LLC holds the strongest active implantable ICP patent position in Western jurisdictions, with at least 4 active US grants spanning 2018 to November 2025, and 2 active EP grants, all covering its gas-reference hermetically sealed catheter architecture. This is the same platform that has achieved FDA clearance and been reported in a first-in-human publication.
Two clinical literature records in this dataset validate long-term ambulatory telemetric ICP monitoring. The NEUROVENT-P-tel telemetric system enabled home ICP telemonitoring in 20 IIH patients from 2014 to 2020, confirming diagnoses in 18 of the 20 patients. An observational study of implantable telesensors in hydrocephalus patients showed significant reductions in neurosurgical service demand and costs.
Southeast University filed a pending CN patent in 2024 incorporating graphene-doped PDMS (Gr-PDMS) as the pressure-sensitive material within an inductive LC resonator. The Gr-PDMS composite shifts the LC resonant frequency proportionally to ICP, enabling inductive readout without any implanted battery. The filing claims improved sensitivity, biocompatibility, and long-term stability compared to conventional MEMS designs.
China dominates filing volume in this dataset with approximately 20 CN-jurisdiction patents from at least 12 distinct Chinese assignees. The US holds 6–7 patents including Branchpoint & Aura Development LLC, NeuCen Biomedical, Longeviti Neuro Solutions, and others. Great Britain and Europe hold patents from NeuCen Biomedical and Branchpoint. India has 4 pending 2025 filings from NIMS University Rajasthan covering non-invasive wearable ICP estimation. PCT/WO and AU filings from Johns Hopkins round out the dataset.
According to the strategic analysis in this dataset, the multimodal convergence trend — combining ICP with brain tissue oxygen saturation (rSO2), temperature, and EEG — is not yet comprehensively protected in Western jurisdictions. This creates a potential opportunity for companies to file integrated multi-parameter cranial monitoring IP in the US and EU before this direction matures, as current protection is concentrated in Chinese filings from Wante Fook Medical (CN 2025) and PLA General Hospital (CN 2021).
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.